Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1

Archives of Virology

Volumn 157, Issue 9, 2012, Pages 1709-1718

  Zhong, Tianhua ^a   Li, Xiao ^a   Zhou, Zhichao ^a   Li, Ting ^a   Tian, Xingui ^a   Zhou, Rong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; HEXON CAPSID PROTEIN, ADENOVIRUS; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CHEMICAL STRUCTURE; FEMALE; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETICS; HUMAN ADENOVIRUS; IMMUNOLOGY; MOUSE;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; EPITOPES; FEMALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MUTAGENESIS, INSERTIONAL; RECOMBINATION, GENETIC;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 3; MIRIDAE;

EID: 84865745739     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1364-1     Document Type: Article

References (34)

1. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3: 137-144.
2. Schagen FH, Ossevoort M, Toes RE, Hoeben RC (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50: 51-70.
3. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.
4. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG (2007) Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 81: 13801-13808.
5. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583.
6. Chen P, Kovesdi I, Bruder JT (2000) Effective repeat administration with adenovirus vectors to the muscle. Gene Ther 7: 587-595.
7. Rux JJ, Burnett RM (2004) Adenovirus structure. Hum Gene Ther 15: 1167-1176.
8. Crawford-Miksza L, Schnurr DP (1996) Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70: 1836-1844.
9. Rux JJ, Kuser PR, Burnett RM (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553-9566.
10. Rux JJ, Burnett RM (2000) Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther 1: 18-30.
11. Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75(Pt 1): 133-139.
12. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382-3390.
13. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688-3701.
14. McConnell MJ, Danthinne X, Imperiale MJ (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361-5370.
15. Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M (2007) Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res 27: 2311-2316.
16. Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus-based cancer gene therapy. Future Oncol 2: 137-143.
17. Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL (2003) Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 63: 1262-1269.
18. Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh V, Douglas JT, Curiel DT (2003) A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 309: 282-293.
19. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356.
20. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W (1999) Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6: 1520-1535.
21. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, Vogt L, Ruedl C, Bachmann MF, Greber UF, Hemmi S (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78: 4454-4462.
22. Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A (2011) Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 18: 288-296.
23. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80: 12109-12120.
24. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT (2002) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8: 275-280.
25. Tuve S, Wang H, Jacobs JD, Yumul RC, Smith DF, Lieber A (2008) Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog 4: e1000189.
26. Zhu ZB, Mathis JM, Makhija SK, Lu B, Wang M, Ji S, Rivera AA, Rosenthal EL, Siegal GP, Curiel DT (2007) Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Int J Oncol 31: 1213-1222.
27. Zhang Q, Su X, Seto D, Zheng BJ, Tian X, Sheng H, Li H, Wang Y, Zhou R (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27: 1145-1153.
28. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A (2006) Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics Chapter 5: Unit 56.
29. Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM (2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81: 1680-1689.
30. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775-12782.
31. Huang XH, Shi ZB, Wang KZ, Dang XQ, Yang P, Yu PB (2008) Construction and identification of recombinant adeno-associated virus vector co-expressing human vascular endothelial growth factor and green fluorescent protein. Journal of clinical rehabilitative tissue engineering research 12: 5755-5758.
32. Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311-320.
33. Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
34. Aguilar LK, Guzik BW, Aguilar-Cordova E (2011) Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112: 1969-1977.